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ABSTRACT
This study was a phase I double-blind, randomized, placebo-controlled trial to evaluate the safety and
immunogenicity of a Serbian-produced seasonal trivalent split, inactivated influenza vaccine in healthy
adults. The vaccine was manufactured in eggs by the Torlak Institute of Virology, Vaccines and Sera,
Belgrade, Serbia and contained A/H1N1, A/H3N2 and B viruses. The clinical trial took place at the Clinical
Center of Serbia in Belgrade. Sixty healthy volunteers, aged 18–45 years, were enrolled in the trial. On the
day of immunization, volunteers were randomly assigned to receive either a single dose of the trivalent
seasonal influenza vaccine (15 mg of hemagglutinin per strain) or placebo (phosphate-buffered saline).
Subjects were monitored for adverse events through a clinical history and physical examination, and
blood was taken for testing at screening and on day 8 to assess vaccine safety. Serum samples obtained
before and 21 days after immunization were tested for influenza antibody titers using hemagglutination-
inhibition (HAI) and microneutralization (MN) tests. No serious adverse events were reported. Pain and
tenderness at the injection site were the most commonly reported symptoms in both vaccine and placebo
groups. Overall, serum HAI responses of fourfold or greater magnitude were observed to H1, H3, and B
antigen in 80%, 75%, and 70% of subjects, respectively. Seroprotection rates as measured by HAI were
also high (100%, 100% and 86.67%, respectively, for H1, H3 and B). Thus, Torlak’s seasonal trivalent
influenza vaccine was not associated with adverse events, was well-tolerated and immunogenic. It should
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Introduction
Influenza is a significant cause of respiratory morbidity and
mortality, with the highest burden of severe disease occurring
in at-risk populations.1,2,3,4 In temperate regions, seasonal
influenza epidemics occur each year during the winter months,
generally between November and April, causing tens of thou-
sands of deaths in Europe alone.5,6 Because of the ability of the
influenza virus to mutate, the strains included in seasonal vac-
cines need to be updated on a regular basis. Annual vaccination
can reduce an individual’s risk of getting influenza and the
World Health Organization (WHO) recommends vaccination
of high-risk groups, including pregnant women, young chil-
dren, individuals with specific chronic diseases, people aged
65 years or over and health care workers.7
Influenza A viruses also have the ability to cause pandemics
when antigenic shift occurs and have caused four pandemics in
the last 100 years, the most severe of which occurred in 1918
and is estimated to have caused over 50 million deaths globally.6
Vaccines are one of the best defences against a pandemic;
however, in 2009, vaccine availability was limited before the sec-
ond wave of the pandemic and deliveries of WHO vaccine dona-
tions to developing countries were significantly delayed.8 The
establishment of local production of influenza vaccines in devel-
oping countries has been promoted by WHO’s Global Action
Plan for Influenza Vaccines (GAP), which was a ten-year strat-
egy to reduce the anticipated shortfall in influenza vaccine sup-
ply during a pandemic.9 Since 2009 the Torlak Institute in
Serbia has participated in GAP’s technology transfer project to
establish local production of influenza vaccines, with support
from international donors, including the Biomedical Advanced
Research and Development Authority (BARDA) of the US
Department of Health and Human Services.10 PATH has also
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been involved in supporting GAP vaccine manufacturers and
more precisely in providing technical assistance to the Torlak
Institute for process development and design and implementa-
tion of phase I clinical trials.11
The Government of Serbia has a policy to immunize people
older than 65 years, those with chronic diseases, pregnant women,
young children, and health care workers, as well as certain travel-
lers.12 As influenza vaccination is not obligatory, uptake differs
from year to year, but the Torlak Institute estimates that between
200 000 and 250 000 doses are used in Serbia each year.
Since joining the GAP programme, the Torlak Institute has
established a process for the production of a seasonal, trivalent,
split, inactivated influenza vaccine produced on eggs; this vac-
cine has been shown to be safe and immunogenic in animal
studies.13 We evaluated the safety profile and immunogenicity
of a single intramuscular dose of the vaccine in healthy adults
in a phase I clinical trial.
Challenge/capacity building
Many challenges were faced during the set-up of the Phase 1 clini-
cal trial. It was the first time that a clinical trial for a vaccine was
performed in Serbia. PATH and WHO supported initiation of a
collaboration between the Serbian Ministry of Health, the national
regulatory agency “Medicines and Medical Devices Agency of Ser-
bia (ALIMS)” and Institute Torlak through the WHO Country
Office (CO) in Serbia. The goal was to engage in monthly meetings
with Torlak and PATH through facilitation by the WHO Serbia
office to ensure that the vaccine programme was moving along
and any issues were resolved immediately. Capacity building
included the strengthening of the ALIMS to assist with vaccines
regulation (GMP enforcement of the domestic vaccine manufac-
turer, approval of clinical trials). Strengthening capacity to conduct
clinical trials in Serbia was also provided to ensure that clinical
sites assessed would be able to perform the phase 1 clinical trial of
Torlak’s seasonal influenza vaccine under Good Clinical Practices
(GCP). An assessment visit by an independent GCP auditor from
Switzerland at the selected clinical site was performed and a Cor-
rective Action Preventive Action (CAPA) plan was shared with
the site prior to study initiation. These recommendations were
addressed through equipment purchases and specific training
activities. WHO/PATH/Torlak developed a crisis communications
plan and trained relevant staff for the seasonal vaccine phase 1 trial
to deal with any crisis or media enquiries that could have arisen
during the trial. Finally, PATH team provided technical assistance
to Torlak in all clinical trial documentation preparation.
Results
Demographic and other baseline characteristics
Sixty-six (66) volunteers were screened for enrolment in the
study. Six patients did not fulfil required inclusion criteria and
finally, 60 healthy male and female adults 18 to 45 years old
from Serbia were enrolled in the study; 30 received the vaccine
and 30 the placebo (Fig. 1 participant flow diagram). All sub-
jects were of white Caucasian race; 18 (30%) were female and
42 (70%) were male, equally divided between vaccine and pla-
cebo groups. The overall mean age was 30.85 years. Basic
demographic characteristics are presented in Table 1. All sub-
jects completed the study and were included in the per-protocol
population analysed for immunogenicity.
Immunogenicity
Baseline HAI and MN seropositivity rates were similar in the
two study groups: in the HAI assay, 27% of subjects receiving
vaccine and 33% of subjects receiving placebo had antibody
titres of 1:40 or more to H1, for H3 this was 63% in both groups
and for B antigen this was 10% in the vaccine group and 17% in
the placebo group; in the MN assay, 33% of subjects receiving
vaccine and 43% of placebo recipients were seropositive to H1,
for H3 antigen this was 23% in vaccinated subjects and 27% in
placebo recipients and for B antigen this was 77% for vacci-
nated subjects and 73% for placebo recipients.
Seroconversion was observed in the majority of vaccinated
subjects in both the HAI and the MN assays. By HAI, 25 of the
30 subjects (83.33%) had a seroconversion response to H1, 23
(76.67%) to H3 and 21 (70%) to the B antigen. None of the pla-
cebo recipients showed a seroconversion response in the HAI
assay (Table 2). In the MN assay, the seroconversion rates for
the three antigens were 83.33% for H1, 70% for H3 and 53.33%
for B. Two subjects in the placebo group showed seroconver-
sion to H1 (6.67%), and two to B (6.67%); none showed sero-
conversion to H3 (Table 2).
Post-vaccination seroprotection rates, as measured by HAI
(titre  1/40), were very high among vaccine recipients: 100%
for H1 and H3 and 86.67% for B. Among those receiving pla-
cebo, the rates were 33.33% for H1, 63.33% for H3 and 16.67%
for H3 (Table 2). Post-vaccination seroprotection rates mea-
sured by MN assay (titer  40) were detected in 93.33% of vac-
cine recipients for H1, 86.67% for H3, and 100% for B. Among
placebo recipients, post-vaccination seroprotection rates were
53.33% for H1, 33.33% for H3, and 80% for B (Table 3).
The geometric mean titers rose significantly among vaccine
recipients for all three antigens, in both the HAI and the MN tests.
GMTs at baseline were low and there was no rise in antibodies
among those given placebo in either test (point estimate for fold
rise for all antigens tested by either test was  1.5). In the HAI
assay, the highest GMT was observed for H3 (439.67) and the
highest fold rise for H1 (18.49). While the GMT for B antigen was
the lowest, it still showed a 7.25-fold increase, from 10.47 (base-
line) to 75.95 (post-vaccination). The MN assays showed similar
trends with regard to fold changes. However, the strongest GMT
response was to B antigen (331.28), followed by H1 (211.12) and
H3 (125.53) (Table 4). None of the placebo recipients developed a
fourfold rise in MN antibodies following vaccination.
The number and corresponding percentage of subjects with
a fourfold or greater rise from baseline as tested by the MN
assay in the vaccine and placebo groups were: for H1, 25
(83.33%) vs 2 (6.67%); for H3, 22 (73.33%) vs 0 (0%); and for B
antigen, 14 (46.67%) vs 2 (6.67%).
Adverse events
No allergic reactions were observed during the 30 minutes after
administration of either Torlak seasonal influenza vaccine or
placebo.
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During the seven days after administration, 32 local solicited
reactions were reported in the vaccine group and six in the pla-
cebo group (Table 5). Pain at the injection site was the most fre-
quently reported solicited local symptom, occurring in 46.66%
(14/30) of those given vaccine and 13.33% (4/30) of those who
received placebo. Other local solicited events were: tenderness
(10 (33.33%) subjects in the vaccine group and one subject
(3.33%) in the placebo group), and redness at injection site
(20% of subjects in the vaccine group and none in the placebo
group). Hardness and swelling were reported by less than 10%
of the subjects. All local solicited events were assessed as mild
in intensity, except for two cases each of pain and tenderness,
which were assessed as moderate. Injection-site AEs lasted for
4–5 days in the vaccination group and up to 3 days in the pla-
cebo group and resolved without treatment.
Systemic adverse events were less commonly reported and
occurred more frequently in the vaccine recipients than placebo
recipients. The majority of those were short-lived and mild in
intensity. The most commonly reported solicited systemic
events were tiredness and headache with each symptom being
Table 1. Demographic characteristics of study subjects.
All subjects Female Male
No. (%) of subjects 60 18 (30) 42 (70)
Mean age (years) 30.85 33.11 29.88
Distribution by age group
20–29 years 30 6 (33.33) 24 (57.14)
30–39 years 21 9 (50) 12 (28.57)
40–45 years 9 3 (16.67) 6 (14.29)
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Figure 1. Participant Flow Chart.
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reported by 16.66% of subjects in vaccine group. None of the
subjects in the placebo group reported tiredness and only
6.67% reported headache. Other systemic solicited events,
reported by fewer than 10% of subjects, included nausea, fever
(axillary temp >37 C), chills, muscle aches, joint aches and
vomiting. Most cases were mild in intensity, with only four epi-
sodes (two of tiredness and one each of muscle aches and head-
ache) reported as moderate (Table 5). All symptoms resolved
within seven days. In all instances, solicited events were
assessed as causally related to the vaccination.
During the 21-day follow-up period, one or more unsolic-
ited adverse events were reported for 6.7% (2/30) of subjects in
both vaccine and placebo groups. Four systemic AEs were
observed in the placebo group: diarrhea, back pain, cough and
increased ALAT levels. Three systemic AEs were reported in
the vaccine group: influenza-like illness, respiratory tract infec-
tion and back pain. All the systemic adverse events were mild
in intensity, except for the one case of back pain in the vaccine
group, which was considered moderate. None of these events
were assessed to be causally related to the treatment
administered.
No deaths, and no serious and significant adverse events
were reported during the conduct of the study.
Mild elevations in liver enzyme levels were observed in a few
subjects in both treatment groups, with no specific pattern or
correlation with treatment. The incidence of abnormal labora-
tory findings was comparable in the two groups. Most episodes
were considered as not clinically significant, except for one
patient in the placebo group, who had a clinically significant
elevation in ALAT (assessed as of mild severity).
Discussion
The remarkable ability of the influenza virus to mutate presents
a significant challenge to public health, which is currently
addressed by yearly identification of circulating strains and
development of matched vaccines.14 D1 Local development of
influenza vaccines, as is being done in Serbia, will allow
expansion of influenza vaccination and significantly reduce
respiratory illnesses and time away from work. Protection from
influenza through vaccination can thus contribute to national
and regional growth and development.
The high baseline titres in over half of the subjects in this
study, particularly to the recently circulating H3 strain, suggest
that influenza is widespread in Serbia. The particularly high
prevalence of H3N2 among the study participants is consistent
with the influenza surveillance report from WHO on seasonal
influenza in Serbia.15
The vaccine used in this study was shown to be safe and well
tolerated. The reactogenicity profile observed, particularly the
frequency and severity of solicited and unsolicited adverse
events, was similar to those of already licensed inactivated sea-
sonal influenza vaccines in adults.16,17 Events included local
reactions at the injection site, typical of those seen with paren-
teral vaccination (pain, tenderness, hardness); reactions were
mostly mild and of short duration. Systemic adverse events,
including laboratory abnormalities, were uncommon, mild,
and of no risk to the health and well-being of the individuals.17 D2
There was no difference in the rate of unsolicited systemic AEs
Table 2. Subjects showing seroconversion in HAI and MN tests, vaccine and
placebo recipients.
HAI MN
Vaccine group No. % (95% CI) No. % (95% CI)
A/H1N1 25 83.33 (65.28–94.36) 25 83.33 (65.28; 94.36)
A/H3N2 23 76.67 (57.72– 90.07) 21 70 (50.60; 85.27)
B 21 70 (50.60–85.27) 16 53.33 (34.33; 71.66)
Placebo group
A/H1N1 0 0 (0–11.57) 2/30 6.67 (0.82–22.07)
A/H3N2 0 0 (0–11.57) 0/30 0 (0–11.57)
B 0 0 (0–11.57) 2/30 6.67 (0.82–22.07)
Table 4. GMT antibody response to influenza H1, H3 and B antigens, by HAI and MN tests, vaccine and placebo groups.
A/H1N1 A/H3N2 B
GMT (95% CI) GMT (95% CI) GMT (95% CI)











































































Table 3. Subjects with seroprotection, by HAI and MN tests, vaccine and placebo
recipients.
HAI MN
Vaccine group No. % (95% CI) No. % (95% CI)
A/H1N1 30 100 (88.43–100) 28 93.33 (77.93–99.18)
A/H3N2 30 100 (88.43–100) 26 86.67 (69.28–96.24)
B 26 86.67 (69.28–96.24) 30 100 (88.43–100)
Placebo group
A/H1N1 10 33.33 (17.29–52.81) 16 53.33 (34.33–71.66)
A/H3N2 19 63.33 (43.86–80.07) 10 33.33 (17.29–52.81)
B 5 16.67 (5.64–34.72) 24 80.00 (61.43–92.29)
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between the vaccine and placebo groups, and the AEs observed
were considered not to be related to the study vaccine. No
SAEs were observed among the vaccine recipients, and no
immediate post-vaccination AEs, such as shock and anaphy-
laxis, were reported.
It should be acknowledged, however, that the sample size in
this phase I clinical study was insufficient to detect AEs occur-
ring at low frequency; the full safety profile of the vaccine is yet
to be determined in larger-scale studies. Testing also needs to
include individuals at higher risk, such as the elderly, individu-
als with pre-existing conditions and pregnant women. Such
testing can be conducted through post marketing surveillance,
once the vaccine has been further evaluated in healthy adults
and licensed.
The results also indicated that the Torlak vaccine is capable
of eliciting robust immune responses, both in na€ıve subjects
and in those previously primed by infection or vaccination.
The immunogenicity criteria required for licensure by the
European Medicines Agency for seasonal vaccines were met
convincingly.18 Seroconversion rates were greater than 80% for
H1, 75% for H3, and 70% for B subtypes, as measured by the
HAI assay. Slightly lower rates for the H3 and B antigens were
observed with the MN test. Seroprotection rates measured by
both HAI and MN assays were over 86% for all three subtypes.
Similarly, substantial rises in GMTs were observed in the HAI
assay in the vaccine group between baseline (pre-immuniza-
tion) and 21 days after immunization for all three strains, indi-
cating a strong immune response against all three vaccine
antigens. GMT ratios (vaccine/placebo) measured by MN assay
were also significantly high, the lowest being >4 for the B anti-
gen. Overall, there was a close correlation between HAI and
MN results in terms of seroconversion and seroprotection rates
and at the individual level. Other studies have demonstrated
correlation between HAI and MN results, as well as the higher
sensitivity of MN assays, particularly for detection of antibodies
to influenza B viruses.19
In conclusion, the Torlak seasonal, trivalent, split, inacti-
vated influenza vaccine was shown to be safe and well tolerated,
and induced high levels of seroconversion and seroprotection
rates in immunologically na€ıve individuals as well as those with
pre-existing HAI antibodies. These clinical data provide a basis




This phase I, double-blind, randomized, placebo-controlled
study had two objectives: to evaluate the safety profile of a sin-
gle intramuscular dose of influenza vaccine and to evaluate its
immunogenicity. The study was conducted at the Clinic for
Infectious and Tropical Diseases, Clinical Centre of Serbia,
Belgrade. Screening tests were conducted on volunteers, who
gave their informed consent to join the study. Volunteers were
randomized to receive either vaccine or placebo on Day 0, prior
to receiving the vaccine blood was taken for baseline immuno-
genicity analyses. During the first week following vaccination,
subjects were asked to record local and systemic signs and
symptoms using pre-printed Memory Aids, a thermometer,
and a small ruler. In addition to solicited signs, subjects were
asked to report any other adverse events. The volunteers
returned to the clinic seven days after vaccination at which
time the study staff reviewed the Memory Aids and transcribed
all solicited reactogenicity and other adverse events onto the
case report forms. At this visit blood was taken for biochemical
and hematological blood tests. Participants returned again for
the clinic for their final visit on Day 21 post vaccination where
blood was taken again for immunogenicity analyses. Partici-
pants were followed up for 90 Days post vaccination with a
final phone call to volunteers on Day 90 (§ 5 days). The
schedule of events are shown in (Supplementary Table 1). The
vaccine was used in accordance with Research Protocol of Vac-
cine Clinical Trial, Protocol Number: TORLAK-100.
Study population
Sixty-six healthy Serbian male and female adult volunteers aged
18–45 years were screened for inclusion in the study. Inclusion
criteria were that subjects were literate (by self-report), healthy
Table 5. Solicited symptoms in the 7-day period after immunization with Torlak seasonal influenza vaccine.
Placebo Vaccine
None Mild Moderate Severe None Mild Moderate Severe
n % n % n % n % n % n % n % n %
Local Hardness 30 100 0 0 0 0 0 0 28 93 2 7 0 0 0 0
Pain 26 87 4 13 0 0 0 0 16 53 12 40 2 7 0 0
Redness 30 100 0 0 0 0 0 0 24 80 6 20 0 0 0 0
Swelling 30 100 0 0 0 0 0 0 28 93 2 7 0 0 0 0
Temperature>37 29 97 1 3 0 0 0 0 28 93 2 7 0 0 0 0
Tenderness 29 97 1 3 0 0 0 0 20 66.7 8 26.7 2 6.7 0 0
Systemic Chills 30 100 0 0 0 0 0 0 28 93 2 7 0 0 0 0
Headache 28 93 2 7 0 0 0 0 25 83 4 13 1 3 0 0
Joint Aches 28 93 2 7 0 0 0 0 29 97 1 3 0 0 0 0
Muscle Aches 29 97 1 3 0 0 0 0 28 93 1 3 1 3 0 0
Nausea 30 100 0 0 0 0 0 0 28 93 2 7 0 0 0 0
Tiredness 30 100 0 0 0 0 0 0 25 83 3 10 2 7 0 0
Vomiting 30 100 0 0 0 0 0 0 29 97 1 3 0 0 0 0

Hardness, Redness, Swelling and Temperature>37 if any are categorized as Mild.
Severity ratings: mild – noticeable but with no effect on activities, moderate – interferes with daily activities, severe – adverse events prevent daily activities.
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(as established by the medical history, physical examination,
and screening laboratory evaluations), capable and willing to
complete a Memory Aid, and willing to return for all follow-up
visits. In addition, the women had to have a negative pregnancy
test, not be breastfeeding, and be willing to use reliable
birth control measures (e.g. intrauterine device, hormonal con-
traception, condoms) for three weeks from the day of vaccina-
tion. Exclusion criteria included: presence of any acute or
chronic illness, taking immunoglobulin or medication that
could interfere with assessment of safety or immunogenicity,
participating in any other clinical trial, hypersensitivity to any
vaccine, chicken or egg protein, and drug or alcohol depen-
dence. Subjects who had received influenza vaccine in the pre-
vious year were also excluded. Participants needed to be
available for vaccination and all follow-up visits.
This study was approved by the ethics review committees of
the Clinical Centre of Serbia, the World Health Organization
and the National Regulatory Agency (ALIMS). Written
informed consent was obtained from all participants before any
study-related activities took place.
Treatments
Eligible subjects were randomized 1:1 to receive either vaccine
or placebo. The seasonal trivalent influenza vaccine tested was
manufactured by the Torlak Institute using embryonated
chicken eggs and supplied in prefilled, single-dose, disposable
syringes. It was a split virion vaccine, inactivated with Beta-pro-
piolactone (BPL) and the virion split with Triton X-100. The
vaccine contained 15 mg of hemagglutinin antigen of each virus
strain recommended for the 2014–15 season in the northern
hemisphere: X-181 reassortant of A/California/7/2009 (H1N1);
X-223A reassortant of A/Texas/50/2012 (H3N2), and NYMC
BX-51B reassortant of B/Massachusetts/2/2012. The placebo,
which was also manufactured by the Torlak Institute, consisted
of phosphate-buffered saline (PBS), pH 7.4, also supplied in
prefilled, single-dose, disposable syringes. The vaccine and pla-
cebo were stored in a refrigerator at a temperature between
2 C and 8 C. The shelf-life was estimated to be 12 months
under these conditions. Storage temperature was monitored
daily and documented. Back-up power or storage was available
in case of primary power failure. The vaccine and placebo
syringes were identically packaged and labelled so that the
study could be conducted in a double-blind manner. Randomi-
zation was performed by an individual not involved in the con-
duct of the study. In the case of any unblinding, researchers
were required to report this in writing to the overseeing Ethics
Committee. The allocation code of the product injected into
each subject was recorded on the case report form.
Safety assessment
Solicited local and systemic reactions and unsolicited adverse
events (AEs) were collected and recorded. Solicited reactions
are local or systemic AEs, typically associated with intramuscu-
lar influenza vaccination, that were specifically asked about
during the 7-day post-vaccination period. Unsolicited events
were reported by the subject or observed by study staff during
clinic visits. Such events were recorded up to 21 days post-
vaccination, except for serious adverse events (SAEs), which
were recorded throughout the entire study period of 90 days. If
a new solicited event was reported by the subject more than
7 days post-vaccination, it was recorded as an unsolicited AE.
Blood was collected for basic clinical chemistry and hematology
at screening and on day 7. Laboratory analyses included biliru-
bin, alanine aminotransferase (ALAT), creatinine, total protein,
white blood cells, hematocrit, hemoglobin, and platelets. All
clinically significant laboratory findings were reported as unso-
licited adverse events. All clinical safety evaluations were made
by a qualified clinician. Any clinical sign, symptom or labora-
tory finding that at any time met the established criteria for an
SAE was categorized as such.
Any solicited local or systemic reaction that occurred during
the 7-day period post-injection was regarded as related to prod-
uct administration.
The study was conducted in accordance with the rules for
good clinical practice (GCP), including International Confer-
ence on Harmonisation guidelines, directive 2001/20/EC of the
European Parliament, and the most recent version of the Decla-
ration of Helsinki.
Assessment of immunogenicity
Serum antibodies detected by hemagglutination inhibition
Hemagglutination inhibition (HAI) is the most frequently used
serological test for determining immunological responses to
influenza vaccination.18 Serum specimens obtained before, and
21 days after, vaccination were tested at the Torlak Diagnostic
Laboratory for the presence and titer of HAI antibodies to each
of the influenza strains in the vaccine. They were re-tested by
VisMederi, laboratory (Siena, Italy) using a validated assay.
HAI antibody titers to the three influenza antigens (H1, H3
and B) were determined in duplicate on separate days, with
paired specimens tested simultaneously. The HAI used 0.5%
turkey red blood cells with the three separate antigens. Serum
samples were treated with receptor-destroying enzyme and
pre-adsorbed on human red blood cells before testing. HAI
assays were performed at a starting dilution of 1:10, with subse-
quent serial twofold dilutions. Each antigen was diluted to eight
HA units (with 50 ml). Titers were determined by identifying
the last well with a total lack of agglutination. If the results for
duplicate samples were more than 2-fold different, the test was
repeated. Samples for which the titer was greater than the last
dilution were diluted further and retested. The final results are
given as the reciprocal titer of the lowest duplicate value.
Serum antibodies detected by microneutralization
The serum samples were tested for the presence of neutralizing
antibodies to each of the influenza strains in the vaccine using
a microneutralization (MN) test. For this, serial dilutions of
serum, along with fixed amount of live influenza vaccine virus,
were added to a culture of Madin-Darby canine kidney
(MDCK) cells. Virus-infected cells exhibit a cytopathic effect
that can be detected by staining. Titers of neutralizing antibod-
ies are expressed as the greatest dilution of serum inducing
50% neutralization of the cytopathic effect in tissue culture
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(TCID50). At the end of the incubation period, each well of the
96-wells microtiter plate is checked under an optical micro-
scope to assess the presence of local lesions (Cytopathic effects
‘CPE’) in the cell lawn. Cytopathic effects (CPE) were defined
as complete destruction of the cell lawn in the well or the pres-
ence of hole(s) in the cell lawn, surrounded by destroyed cells.
An incomplete or not overgrown cell lawn with hole(s) sur-
rounded by intact cells is not regarded as CPE. Cell control was
characterized by an intact cell lawn, meaning that the cells have
not been infected. When compared with the cell control, the
wells which show CPE are regarded as “positive” (infected),
while the wells which don’t show CPE are defined as “negative”
(protected).
The method used to perform the microneutralization test is
based on the production of serum dilution series and on the
fact that each dilution step of the single serum is repeated in 8
wells into the single microtiter plate (8 repetitions). This results
in a very reliable determination of the neutralization titre (Nt).
The Nt in this particular test is defined as the serum dilution
by means of which 50% of the wells are protected against a
virus-induced cytopathogenic effect (CPE). The Spearman-
K€arber formula is used to calculate the NT, providing correct
results where:
– a lowest dilution with 100% protection;
– a highest dilution with 0% protection, and
– at least one dilution with over 0% but less than 100% pro-
tection are involved.
In the event that no well exhibits protection at all (meaning
that all wells exhibit CPE) the neutralization titre is determined
as the exact half of the titre that would result if one single well
was protected.
Statistical methods
The primary objective of the study was to evaluate the safety of
one dose of the vaccine. The sample size was selected based on
logistical considerations. Immunogenicity requirements were
not considered in the choice of sample size since this was a sec-
ondary objective. Sample size for this study was 60 healthy
male and female adults, 18 to 45 years old, 30 subjects per
group.
Safety analysis
The vaccine safety profile was assessed in terms of the number
and percentage of subjects with: (1) adverse events occurring
within 30 minutes after vaccination; (2) solicited local and sys-
temic reactions within seven days post-vaccination; (3) unsolic-
ited adverse events within 21 days post-vaccination (including
changes in clinical laboratory parameters); and (4) SAEs occur-
ring within 90 days post-vaccination. Two-sided exact 95%
confidence intervals (CIs) were calculated. For solicited AEs,
Fisher’s exact test was used to compare the proportions of reac-
tions in the two treatment groups.
Immunogenicity analysis
Immunogenicity assessments included: number and percentage
of subjects with a serum HAI antibody titer  1:40
(seroprotection titer) 21 days post-vaccination for each of the 3
antigens; number and percentage of subjects seroconverting for
each of the 3 antigens (seroconversion was defined as a serum
HAI titer on day 21 meeting one of the following criteria: (1)
pre-vaccination titer <1:10 and post-vaccination titer  1:40,
or (2) pre-vaccination titer  1:10 and at least a four-fold
increase in post-vaccination titer); geometric mean titers
(GMTs) of serum HAI antibodies pre- and post-vaccination for
each of the three antigens; rise in GMTs of serum HAI antibod-
ies for each of the three antigens; number and percentage of
subjects with a fourfold rise in MN titer for each of the anti-
gens; GMTs of MN antibodies for each of the three antigens.
The percentages of subjects with an immune response were
calculated, along with the corresponding two-sided exact 95%
(Clopper-Pearson) CIs. GMT was summarized by treatment
group, along with the corresponding two-sided 95% CIs, by
exponentiation the corresponding log-transformed means and
their 95% CIs. No multiplicity adjustment to the error rate,
alpha, was made because the exploratory nature of the study
meant that no formal statistical hypothesis was being tested.
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